Prussia, Pennsylvania-based Universal Health Services, Inc. (UHS) is one of the largest hospital and healthcare service providers in the U.S. and the U.K. With a market cap of $10.4 billion, the company operates through two core businesses: Acute Care Services and Behavioral Health Services. Its broad network includes hospitals, emergency departments, behavioral health facilities, outpatient centers, physician services, and health insurance offerings
Shares of this health care giant have notably struggled to keep up with the broader market over the past year. UHS has declined 5% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 18.3%. The disconnect has become even starker in 2026, with UHS down 19.1% year to date while the broader benchmark has advanced 11.8%.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
The stock’s struggles stand out even more against its healthcare peers. The State Street SPDR S&P Health Care Services ETF (XHS) has surged 37.7% over the past year and is up 27.4% in 2026, highlighting just how sharply UHS has fallen behind.
www.barchart.com On July 27, United Healthcare released its FY2026 Q2 earnings, and its shares rose 2.3%. Revenue rose 8.3% year over year to $4.64 billion, supported by growth across both its Acute Care and Behavioral Health businesses. Adjusted net income improved 3% to $358.45 million, while adjusted EPS rose 11.8% to $5.98.
Despite the strong revenue growth, UHS revised its 2026 guidance, narrowing revenue expectations to $18.50 billion to $18.76 billion and lowering its Adjusted EBITDA forecast to $2.61 billion to $2.72 billion and adjusted EPS outlook to $22.28 to $23.65. At the midpoint, the new guidance represents a 0.2% increase in expected revenue but 1.9% and 2.6% reductions in Adjusted EBITDA and adjusted EPS, respectively, versus the original forecast.
For the current fiscal year, ending in December, analysts expect UHS’ EPS to grow 6.2% to $23.08 on a diluted basis. The company’s earnings surprise history is mixed. It beat the consensus estimate in three of the last four quarters while missing the forecast on another occasion.
Among the 20 analysts covering UHS stock, the consensus is a “Moderate Buy.” That’s based on six “Strong Buy” ratings, 13 “Holds,” and one “Moderate Sell.”
www.barchart.com This configuration is more bearish than two months ago, with seven analysts suggesting a “Moderate Buy.”
On Aug. 3, RBC Capital analyst Ben Hendrix maintained a “Sector-Perform” rating on UHS while trimming his price target to $183 from $190, implying a modest 7.3% upside from the stock’s then-current price.
The mean price target of $192.24 represents a 9% premium to UHS’ current price levels. The Street-high price target of $290 suggests an ambitious upside potential of 64.4%.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
CrowdStrike Stock Faces a High Bar Ahead of Q2 Earnings. Here’s What Investors Should Watch. This Nvidia Earnings Trade Offers a High Probability of Success Stock Index Futures Climb as Chipmakers Rebound and Bond Yields Fall, U.S. Economic Data in Focus Treasuries Have Reclaimed the Yield Crown From Dividend Stocks. Here’s How Income Investors Can Adapt.